Complement C3 inhibition in severe COVID-19 using compstatin AMY-101

Complement C3 inhibition in severe COVID-19 using compstatin AMY-101

Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating a C3 inhibitor, AMY-101, in severe COVID-19 (PaO2/FiO2

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Skendros, Panagiotis, Germanidis, Georgios, Mastellos, Dimitrios C, Antoniadou, Christina, Gavriilidis, Efstratios, Kalopitas, Georgios, Samakidou, Anna, Liontos, Angelos, Chrysanthopoulou, Akrivi, Ntinopoulou, Maria, Kogias, Dionysios, Karanika, Ioanna, Smyrlis, Andreas, Cepaityte, Dainora, Fotiadou, Iliana, Zioga, Nikoleta, Mitroulis, Ioannis, Gatselis, Nikolaos K, Papagoras, Charalampos, Metallidis, Simeon, Milionis, Haralampos, Dalekos, George N, Willems, Loek, Persson, Barbro, Manivel, Vivek Anand, Nilsson, Bo, Connolly, E. Sander, Iacobelli, Simona, Papadopoulos, Vasileios, Calado, Rodrigo T, Huber-Lang, Markus, Risitano, Antonio M, Yancopoulou, Despina, Ritis, Konstantinos, Lambris, John D
Format: Artikel
Sprache:eng
Schlagworte:
Cardiac and Cardiovascular Systems
Kardiologi
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating a C3 inhibitor, AMY-101, in severe COVID-19 (PaO2/FiO2
DOI:10.1126/sciadv.abo2341